东亚ACS患者PCI术后消化道出血风险评分系统的开发与验证
本研究为BleeMACS国际多中心注册研究的事后分析,纳入15 401例接受PCI的ACS患者,其中东亚组2 332例。基于Fine-Gray模型开发了包含7个预测因子的整数风险评分系统,主要终点为出院后1年消化道出血。结果显示该评分系统具有中等区分度与优异校准性能,东亚患者消化道出血发生率高于非东亚患者且后期风险持续。
要点
- 评分纳入7个预测因子:入院血红蛋白、年龄、高血压、心力衰竭病史、消化道溃疡、质子泵抑制剂应用、出血史。
- 东亚ACS患者PCI术后1年消化道出血累积发生率高于非东亚患者,后期出血事件占比更高。
- 该评分系统在东亚人群及各临床亚组中表现稳定,可用于出血风险分层。
核心结论
- 本研究构建的消化道出血风险评分系统具有中等水平的区分度与优异的校准性能,在东亚人群及各临床亚组中均表现稳定。
- 东亚ACS患者PCI术后消化道出血发生率较高且风险持续至后期,提示需延长监测并实施个体化抗栓治疗策略。
研究设计与样本
- 本研究为BleeMACS国际多中心注册研究的事后分析,纳入2003年11月至2014年6月来自10个国家15家医院接受PCI的ACS患者。
- 共纳入15 401例ACS患者,年龄(63.6±12.7)岁,女性3 592例(23.32%),东亚组2 332例,非东亚组13 069例。
- 采用Fine-Gray模型筛选预测因子并构建整数风险评分系统,以LASSO竞争风险回归进行敏感性分析,Bootstrap重抽样进行内部验证。
主要发现
- 随访1年期间共发生160例PCI术后消化道出血事件。
- 东亚组事件累积发生率高于非东亚组[34例(1.46%)比126例(0.96%)]。
- 后期(181~365 d)出血事件占比东亚组更高[14例(41.2%)比41例(32.5%)]。
- 总体队列中高风险组与低风险组的1年累积出血发生率之比为3.93。
- 东亚组Gray检验P=0.116,风险分层组间差异无统计学意义,但东亚组高、低风险亚组的累积出血风险比为2.72。
关键数值与推荐
- 入院血红蛋白:SHR=0.82,95%CI 0.74~0.90。
- 年龄:SHR=1.02,95%CI 1.01~1.04。
- 高血压:SHR=1.57,95%CI 1.10~2.25。
- 心力衰竭病史:SHR=1.97,95%CI 1.08~3.57。
- 消化道溃疡:SHR=3.25,95%CI 1.41~7.52。
临床怎么用
- 对于东亚ACS患者PCI术后,可应用该评分系统进行消化道出血风险分层。
- 东亚患者后期出血风险持续,需延长监测并考虑个体化抗栓治疗策略。
局限性
- 东亚组风险分层组间差异无统计学意义(Gray检验P=0.116),该评分系统在东亚组内部的风险区分能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To develop and validate a risk scoring system for post-percutaneous coronary intervention (PCI) gastrointestinal bleeding in East Asian patients with acute coronary syndrome (ACS) based on the Fine-Gray model. Methods: This post-hoc analysis was performed on the BleeMACS international multicenter registry study. Patients with ACS undergoing PCI from 15 hospitals across 10 countries between November 2003 and June 2014 were enrolled and stratified into the East Asian group (China and Japan) and the non-East Asian group (other countries). The Fine-Gray model was used to screen predictors and construct an integer-based risk scoring system, with LASSO competing-risk regression for sensitivity analysis. The primary endpoint was gastrointestinal bleeding within 1 year after discharge, with death treated as a competing risk event. Bootstrap resampling was applied for internal validation. Calibration performance was assessed using calibration slope, intercept, and expected-to-observed (E/O) risk ratio. Risk stratification was performed using the Aalen-Johansen cumulative incidence function curve and Gray's test. The temporal distribution of bleeding events was analyzed, and subgroup analyses were conducted according to sex, diabetes mellitus, chronic kidney disease, and dual antiplatelet therapy (DAPT) status. Results: A total of 15 401 ACS patients were enrolled, with an age of (63.6±12.7) years and 3 592 females (23.32%). There were 2 332 patients in the East Asian group and 13 069 in the non-East Asian group. The final model incorporated seven predictors: admission hemoglobin (subdistribution hazard ratio (SHR)=0.82, 95%CI 0.74-0.90), age (SHR=1.02, 95%CI 1.01-1.04), hypertension (SHR=1.57, 95%CI 1.10-2.25), history of heart failure (SHR=1.97, 95%CI 1.08-3.57), peptic ulcer (SHR=3.25, 95%CI 1.41-7.52), proton-pump inhibitor use (SHR=1.54, 95%CI 1.12-2.12), and bleeding history (SHR=1.65, 95%CI 0.98-2.78). The bootstrap-corrected C-index was 0.693 (95%CI 0.652-0.738), with a calibration slope of 0.969 and an E/O ratio of 0.99, indicating favorable overall calibration performance. Risk stratification showed that the bleeding risk in the high-risk group was 3.93 times that in the low-risk group in the overall cohort. For the East Asian group, Gray's test P=0.116, with no significant difference among risk strata. The trend of bleeding risk was consistent with that of the overall cohort, and the ratio of cumulative bleeding risk between the high-and low-risk subgroups was 2.72 in the East Asian group. During the 1-year follow-up, 160 cases of post-PCI gastrointestinal bleeding occurred. The cumulative incidence was higher in East Asian patients than in non-East Asian patients (34 cases (1.46%) vs. 126 cases (0.96%)), with a higher proportion of late bleeding events (181-365 days) (14 cases (41.2%) vs. 41 cases (32.5%)). Subgroup analyses demonstrated stable risk stratification and good calibration performance across clinical subgroups. Conclusions: The gastrointestinal bleeding risk scoring system established in this study exhibits acceptable discrimination and excellent calibration, with stable performance in East Asian populations and various clinical subgroups. East Asian ACS patients have a higher incidence of post-PCI gastrointestinal bleeding with persistent late risk, indicating the need for prolonged monitoring and individualized antithrombotic therapy strategies. 目的: 基于Fine-Gray模型开发并验证适用于东亚急性冠脉综合征(ACS)患者经皮冠状动脉介入治疗(PCI)术后消化道出血的风险评分系统。 方法: 本研究为BleeMACS国际多中心注册研究的事后分析,纳入2003年11月至2014年6月来自10个国家15家医院接受PCI的ACS患者。按地域分为东亚组(中国和日本)与非东亚组(其余国家)。采用Fine-Gray模型筛选预测因子并构建整数风险评分系统,以LASSO竞争风险回归进行敏感性分析。主要终点事件为出院后1年消化道出血,死亡作为竞争风险事件。采用Bootstrap重抽样进行内部验证,通过校准斜率、截距及期望风险与观察风险比值评估校准性能;采用Aalen-Johansen累积发生函数曲线及Gray检验进行风险分层;同时分析出血事件时间分布并按性别、糖尿病、慢性肾脏病、是否接受双联抗血小板治疗开展亚组分析。 结果: 共纳入15 401例ACS患者,年龄(63.6±12.7)岁,女性3 592例(23.32%)。东亚组2 332例,非东亚组13 069例。最终模型纳入7个预测因子:入院血红蛋白[亚分布风险比(SHR)=0.82,95%CI 0.74~0.90]、年龄(SHR=1.02,95%CI 1.01~1.04)、高血压(SHR=1.57,95%CI 1.10~2.25)、心力衰竭病史(SHR=1.97,95%CI 1.08~3.57)、消化道溃疡(SHR=3.25,95%CI 1.41~7.52)、质子泵抑制剂应用(SHR=1.54,95%CI 1.12~2.12)和出血史(SHR=1.65,95%CI 0.98~2.78)。Bootstrap重抽样校正后C指数为0.693(95%CI 0.652~0.738),模型校准斜率0.969、期望风险与观察风险比值0.99,模型整体校准性能优异。风险分层显示,总体队列中高风险组与低风险组的1年累积出血发生率之比为3.93;东亚组Gray检验P=0.116,风险分层组间差异无统计学意义,但风险趋势与总体队列一致,东亚组高、低风险亚组的累积出血风险比为2.72。随访1年期间,共发生160例PCI术后消化道出血事件,东亚组事件累积发生率高于非东亚组[34例(1.46%)比126例(0.96%)],且后期(181~365 d)出血事件占比更高[14例(41.2%)比41例(32.5%)]。亚组分析显示模型在各临床亚组中风险分层稳定、校准性能良好。 结论: 本研究构建的消化道出血风险评分系统具有中等水平的区分度与优异的校准性能,在东亚人群及各临床亚组中均表现稳定。东亚ACS患者PCI术后消化道出血发生率较高且风险持续至后期,提示需延长监测并实施个体化抗栓治疗策略。.
引用
- Zheng, Gong, Li, et al. [Development and validation of a prediction score for gastrointestinal bleeding following percutaneous coronary intervention in East Asian patients with acute coronary syndrome]. Zhonghua Xin Xue Guan Bing Za Zhi. 2026. PMID: 42595519. doi:10.3760/cma.j.cn112148-20260105-00010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。